Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 15/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462930 | 0.93 | EGLN2 (0.44) | EGLN2TSHRGLANPSR1ALDH1A1 | |
| SCHEMBL4705172 | 0.90 | EGLN2 (0.48) | EGLN2TSHRGLANPSR1ALDH1A1 | |
| SCHEMBL5162613 | 0.89 | EGLN2 (0.47) | EGLN2TSHRGLANPSR1ALDH1A1 | |
| SCHEMBL4706706 | 0.87 | EGLN2 (0.46) | EGLN2TSHRGLANPSR1ALDH1A1 | |
| SCHEMBL5593422 | 0.83 | EGLN2 (0.41) | EGLN2TSHRGLANPSR1ALDH1A1 | |
| SCHEMBL5746793 | 0.82 | EGLN2 (0.43) | EGLN2TSHRGLANPSR1ALDH1A1 | |
| SCHEMBL5593357 | 0.81 | KDM1A (0.41) | EGLN2TSHRGLANPSR1ALDH1A1 | |
| SCHEMBL4819346 | 0.79 | EGLN2 (0.42) | EGLN2TSHRGLANPSR1ALDH1A1 | |
| SCHEMBL3423833 | 0.79 | EGLN2 (0.42) | EGLN2TSHRGLANPSR1ALDH1A1 | |
| SCHEMBL5593085 | 0.79 | EGLN2 (0.46) | EGLN2TSHRGLANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148227-B2 | Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungi and agents containing said substances | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050176736-A1 | Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungi and agents containing said substances | BASF AKTIENGESELLSCHAFT (DE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176736-A1 | Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungi and agents containing said substances | CBR1, CBR3, HAO1 | EGLN2 1794/4885TSHR 2394/4885GLA 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.